


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound of the formula I



in which

- R^1 is Het¹, or is a phenyl or naphthyl radical, each of which is unsubstituted or substituted by R^2 and/or R^3 ,
- R^2 and R^3 are each, independently of one another, Hal, A, OA, OH or CN,
- R^4 is H, CN, acyl having 1-6 C atoms, Hal, A, OA, OH, CONH₂, CONHA or CONA₂,
- R^5 is H,
- R^4 and R^5 together are alternatively alkylene having 3-5 carbon atoms,
- Het¹ is a monocyclic unsaturated heterocyclic ring system which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA or OH and which contains one, two or three identical or different heteroatoms selected from nitrogen, oxygen or sulfur,
- A is alkyl having 1-6 carbon atoms,
- Hal is F, Cl, Br or I,


wherein the R^1 -CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole structure ring and the R^4 group is attached to the 5-membered ring of the

indole structure, and


where the indole ring may be replaced by an isatin unit ; [[,]] or
a physiologically acceptable salt or solvate thereof;
with the proviso that said compound is not (1*H*-indol-5-yl)-(4-
phenethylpiperazin-1-yl)methanone.

2. (Currently Amended): A process for the preparation of a compound according to Claim
1, comprising:

a) reacting a compound of formula II




in which L is Cl, Br, I or a free or reactively functionally modified OH group,
with a compound of formula III




or

b) reacting a compound of formula IV



with a compound of formula V



in which L is Cl, Br, I or a free or reactively functionally modified OH group,

or

c) one of the radicals R^1 , R^4 and/or R^5 of a compound of claim 1 is converted into another radical R^1 , R^4 and/or R^5 by cleaving an OA group to form an OH group and/or converting a CHO group into a CN group, wherein A is alkyl having 1 to 6 carbon atoms,

and/or

d) a base compound of claim 1 is converted into one of its salts by treatment with an acid,

and/or

e) a compound of claim 1 is converted into one of its solvates by dissolution in a solvent.

3. (Cancelled):

4. (Cancelled):

5. (Previously Presented): A method for treating psychosis, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, bulimia, nervous anorexia, premenstrual syndrome and/or for positively influencing obsessive-compulsive

disorder (OCD), comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.

6. (Previously Presented): A pharmaceutical composition comprising at least one compound medicament according to Claim 1, and a carrier.
7. (Previously Presented): A method of preparing a medicament having a 5-HT_{2A} receptor antagonistic action comprising combining a compounds according to Claim 1 with a carrier.
8. (Cancelled):
9. (Previously Presented): A compound according to claim 1, wherein said compound is in the form of a hydrate or an alcoholate.
10. (Currently Amended): A compound according to claim 1, wherein R⁴ is H, CN, formyl, acetyl, propionyl, butyryl, trifluoroacetyl, Hal, A, OA, OH, CONH₂, CONHA or CONA₂, A is alkyl having 1 to 6 carbon atoms and Hal is F, Cl, Br, or I.
11. (Previously Presented): A compound according to claim 1, wherein R¹ is phenyl, p-chlorophenyl, p-fluorophenyl, thiophen-2-yl, 5-chlorothiophen-2-yl, 2,5-dichlorothiophen-3-yl and 2- or 3-furyl.
12. (Currently Presented): A compound according to claim 1, wherein R⁴ is H, Hal, alkyl having 1-6 C atoms, alkoxy having 1-6 C atoms, hydroxyl, cyano or acyl having 1-6 C atoms, and Hal is F, Cl, Br, or I.
13. (Currently Amended): A compound according to claim 1, wherein R⁴ is H, Hal, A, OA, OH, CN or acyl having 1-6 C atoms, A is alkyl having 1 to 6

carbon atoms and Hal is F, Cl, Br, or I.

14. (Cancelled):

15. (Cancelled):

16. (Cancelled):

17. (Previously Presented): A compound according to claim 1, wherein R¹ is a phenyl radical which is unsubstituted or substituted by R² and/or R³.

18. (Previously Presented): A compound according to claim 9, wherein R¹ is a phenyl radical which is unsubstituted or substituted by R² and/or R³.

19. (Previously Presented): A compound according to claim 1, wherein R¹ is phenyl.


20. (Previously Presented): A compound according to claim 1, wherein R¹ is phenyl which is unsubstituted or monosubstituted by Hal.

21. (Previously Presented): A compound according to claim 1, wherein R¹ is Het¹ or phenyl which is monosubstituted by Hal.

22. (Currently Amended): A compound according to claim 1, wherein R¹ is Het¹ or phenyl which is unsubstituted or monosubstituted by Hal, ~~and~~ Het¹ is an unsaturated heterocyclic ring system which is unsubstituted or mono- or disubstituted by Hal or A and contains one or two identical or different heteroatoms selected from nitrogen, oxygen and sulphur, A is alkyl having 1 to 6 carbon atoms and Hal is F, Cl, Br, or I.

23. (Currently Amended): A compound according to claim 1, wherein R¹ is Het¹ or phenyl which is unsubstituted or monosubstituted by Hal, R⁴ is H, Hal or A, and Het¹ is an a monocyclic unsaturated heterocyclic ring system which is unsubstituted or mono- or disubstituted by Hal or A and contains one or two identical or different heteroatoms selected from nitrogen, oxygen and sulphur, A is alkyl having 1 to 6 carbon atoms and Hal is F, Cl, Br, or I.

24. (Currently Amended): A compound according to ~~claim 1~~, formula I



wherein

R¹ is Het¹ or phenyl which is unsubstituted or monosubstituted by Hal,
R⁴ is and R⁵ are in each case independently of one another H, Hal or A, or
R⁴ and R⁵ together are alkylene having 3-5 C atoms, and
Het¹ is thienyl or furyl which is unsubstituted or mono- or disubstituted by Hal
or A,

A is alkyl having 1-6 carbon atoms, and

Hal is F, Cl, Br or I,

wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or

7-position of the indole ring, and


where the indole ring may be replaced by an isatin unit; or

a physiologically acceptable salt or solvate thereof;

with the proviso that said compound is not (1H-indol-5-yl)-(4-

phenethylpiperazin-1-yl)methanone.

25. (Currently Amended): A compound according to ~~claim 1~~, formula I



wherein

R^1 is Het¹ or phenyl which is unsubstituted or monosubstituted by Hal,

R^4 is H, Hal, CN, acyl having 1 to 6 C atoms or A,

R^5 is H, or

R^4 and R^5 together are alkylene having 3-5 C atoms, and

Het¹ is thienyl or furyl which is unsubstituted or mono- or disubstituted by Hal or A,

A is alkyl having 1-6 carbon atoms, and

Hal is F, Cl, Br or I,


wherein the R^1 -CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and

where the indole ring may be replaced by an isatin unit; or

a physiologically acceptable salt or solvate thereof;

with the proviso that said compound is not (1H-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone.

26. (Currently Amended): A compound according to ~~claim 1~~, formula I



in which wherein

R¹ is Het¹ or-phenyl or naphthyl which is unsubstituted or monosubstituted by Hal,

R⁴ is H, Hal, CN, acyl having 1 to 6 C atoms, ~~or~~ A or CONH₂,

R⁵ is H, or

R⁴ and R⁵ together are alkylene having 3-5 C atoms, and

Het¹ is thienyl or furyl which is unsubstituted or mono- or disubstituted by Hal or A,

A is alkyl having 1-6 carbon atoms, and

Hal is F, Cl, Br or I,

wherein the indole ring is optionally replaced by an isatin ring

wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and

where the indole ring may be replaced by an isatin unit, or a physiologically acceptable salt or solvate thereof;

with the proviso that said compound is not (1*H*-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone.

27. (Previously Presented): A compound selected from according to claim 1, ~~wherein said compound is:~~

(a) (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone or a physiologically acceptable salt or solvate thereof, ~~or~~ and

(b) (3-aminocarbonyl-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone or a physiologically acceptable salt or solvate thereof.

28. (Previously Presented): A compound according to claim 27, wherein said compound is in the form of a hydrate or an alcoholate.

29. (Previously Presented): A method for treating psychosis, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, bulimia, nervous anorexia, premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD), comprising administering to a patient in need thereof an effective amount of a compound according to claim 27.

30. (Previously Presented): A pharmaceutical composition comprising at least one compound according to Claim 27 and a carrier.

31. (Previously Presented): A method for treating psychosis, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, bulimia, nervous anorexia, a sleep disorder, sleep apnoea, premenstrual syndrome, prophylaxis and combating of the consequences of cerebral infraction, strokes, and cerebral ischaemia, and/or for positively influencing obsessive-compulsive disorder, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.


32. (Previously Presented): A method for treating psychosis, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, bulimia, nervous anorexia, a sleep disorder, sleep apnoea, premenstrual syndrome, prophylaxis and combating of the consequences of cerebral infraction, strokes, and cerebral ischaemia, and/or for positively influencing obsessive-compulsive disorder, comprising administering to a patient in need thereof an effective amount of a compound according to claim 27.

33. (Previously Presented): A method for treating a sleep disorder comprising

administering to a patient in need thereof an effective amount of a compound according to claim 1.

34. (Previously Presented): A method for treating a sleep disorder comprising administering to a patient in need thereof an effective amount of a compound according to claim 27.

35. (Currently Amended) A compound of the formula I



in which

R¹ is Het¹ or is a phenyl or naphthyl radical, each of which is unsubstituted or substituted by R² and/or R³,

R² and R³ are each, independently of one another, Hal, A, OA, OH or CN,

R⁴ is H, CN, acyl having 1-6 C atoms, Hal, A, OA, OH, CONH₂, CONHA or CONA₂,

R⁵ is H,

R⁴ and R⁵ together are alternatively alkylene having 3-5 carbon atoms,

Het¹ is 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-,

3- or 4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6 or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzthiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl,

A is alkyl having 1-6 carbon atoms,

Hal is F, Cl, Br or I,


wherein the R^1 -CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole structure and R^4 is attached to the 5-membered ring of the indole structure, and

where the indole ring may be replaced by an isatin unit, or

a physiologically acceptable salt or solvate thereof;

with the proviso that said compound is not (1*H*-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone.

36. (Previously Presented): A compound of the formula I



in which

R^1 is Het¹ or a naphthyl radical which is unsubstituted or substituted by R^2 and/or R^3 ,

R^2 and R^3 are each, independently of one another, Hal, A, OA, OH or CN,

R^4 and R^5 are each, independently of one another, H, CN, acyl having 1-6 C atoms,

Hal, A, OA or OH,

R⁴ and R⁵ together can also be alkylene having 3-5 C atoms,


Het¹ is 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzthiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl,

A is alkyl having 1-6 carbon atoms,

Hal is F, Cl, Br or I,

and where the indole ring may be replaced by an isatin unit, or a physiologically acceptable salt or solvate thereof.

37. (Previously Presented): A compound of the formula I



in which

R^1 is Het¹ or a naphthyl radical which is unsubstituted or substituted by R^2 and/or R^3 ,

R^2 and R^3 are each, independently of one another, Hal, A, OA, OH or CN,

R^4 and R^5 are each, independently of one another, H, CN, acyl having 1-6 C atoms, Hal, A, OA or OH,

R^4 and R^5 together can also be alkylene having 3-5 C atoms,


Het¹ is a monocyclic unsaturated heterocyclic ring system which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA or OH and which contains one, two or three identical or different heteroatoms selected from nitrogen, oxygen or sulfur,

A is alkyl having 1-6 carbon atoms,

Hal is F, Cl, Br or I,

and where the indole ring may be replaced by an isatin unit, or a physiologically acceptable salt or solvate thereof.

38. (Currently Amended): A compound of the formula I




in which

R^1 is Het¹ or is a phenyl or naphthyl radical, which in each case is unsubstituted or substituted by R^2 and/or R^3 ,

R^2 and R^3 are each, independently of one another, Hal, A, OA, OH or CN,

R^4 is CN, acyl having 1-6 C atoms, Hal, A, OA or OH,
 R^5 is H, CN, acyl having 1-6 C atoms, Hal, A, OA or OH,
 R^4 and R^5 together can also be alkylene having 3-5 C atoms,
 Het^1 is a monocyclic ~~or bicyclic~~ unsaturated heterocyclic ring system which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA or OH and which contains one, two or three identical or different heteroatoms selected from nitrogen, oxygen or sulfur,
A is alkyl having 1-6 carbon atoms, and
Hal is F, Cl, Br or I,
wherein the R^1 -CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and
where the indole ring may be replaced by an isatin unit, or a physiologically acceptable salt or solvate thereof.

39. (Currently Amended): A compound of the formula I



in which

R^1 is Het^1 or is a phenyl or naphthyl radical, which in each case is unsubstituted or substituted by R^2 and/or R^3 ,
 R^2 and R^3 are each, independently of one another, Hal, A, OA, OH or CN,
 R^4 is H, CN, acyl having 1-6 C atoms, Hal, A, OA or OH,
 R^5 is CN, acyl having 1-6 C atoms, or Hal,
 R^4 and R^5 together can also be alkylene having 3-5 C atoms,
 Het^1 is a monocyclic ~~or bicyclic~~ unsaturated heterocyclic ring system which is

unsubstituted or monosubstituted or disubstituted by Hal, A, OA or OH
and which contains one, two or three identical or different heteroatoms
selected from nitrogen, oxygen or sulfur,

A is alkyl having 1-6 carbon atoms, and

Hal is F, Cl, Br or I,

wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and

where the indole ring may be replaced by an isatin unit, or
a physiologically acceptable salt or solvate thereof.

40. (Previously Presented): A compound according to claim 36, wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring.

41. (Previously Presented): A compound according to claim 37, wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring.


42. (Previously Presented): A compound according to claim 38, wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring.

43. (Previously Presented): A compound according to claim 39, wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring.

44. (Previously Presented): A compound according to claim 36, wherein the R¹ is Het¹.

45. (Previously Presented): A compound according to claim 36, wherein R¹ is p-chlorophenyl, p-fluorophenyl, thiophen-2-yl, 5-chlorothiophen-2-yl, 2,5-dichlorothiophen-3-yl, 2-furyl or 3-furyl.

46. (Currently Amended): A compound of the formula I



in which

R¹ is Het¹ or is a phenyl or naphthyl radical, each of which is unsubstituted or substituted by R² and/or R³,

R² and R³ are each, independently of one another, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, OH or CN,

R⁴ is H, CN, formyl, acetyl, propionyl, butyryl, trifluoroacetyl, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, ~~methoxy, ethoxy,~~ n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, OH, CONH₂, CONHA or CONA₂,

- A is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, or 1,1,2- or 1,2,2-trimethylpropyl,
- R⁵ is H, CN, formyl, acetyl, propionyl, butyryl, trifluoroacetyl, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, OH, CONH₂, CONHA or CONA₂,
- R⁴ and R⁵ together are alternatively alkylene having 3-5 carbon atoms,
- Het¹ is 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzthiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl,
- A is alkyl having 1-6 carbon atoms,

Hal is F, Cl, Br or I,

wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and

where the indole ring may be replaced by an isatin unit, or

a physiologically acceptable salt or solvate thereof;

with the proviso that said compound is not (1*H*-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone.

47. (Previously Presented): A compound selected from:

(1*H*-indol-4-yl)-(4-phenethylpiperazin-1-yl)methanone;

(1*H*-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;

(3-formyl-1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-6-yl)-[4-phenethylpiperazin-1-yl]methanone;

(1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-6-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-6-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-6-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone,

(1*H*-indol-6-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;

(3-formyl-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(3-cyano-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone;
(1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(1*H*-indol-7-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
(1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(1*H*-indol-7-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
(1*H*-indol-7-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
(3-formyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone,
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-(4-phenethylpiperazin-1-yl)methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone; and
physiologically acceptable salts and solvates thereof.

48. (Previously Presented): A compound according to claim 47, wherein said compound is (1*H*-indol-4-yl)-(4-phenethylpiperazin-1-yl)methanone, hydrochloride;
(1*H*-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(1*H*-indol-4-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone, hydrochloride;
(3-formyl-1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(1*H*-indol-6-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;
(1*H*-indol-6-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;
(1*H*-indol-6-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone, hydrochloride;
(1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;
(3-formyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride; or
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-(4-phenethylpiperazin-1-yl)methanone, hydrochloride.

49. (Previously Presented): A compound according to claim 47, wherein said compound is selected from:

(1*H*-indol-4-yl)-(4-phenethylpiperazin-1-yl)methanone;
 (1*H*-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
 (1*H*-indol-4-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
 (1*H*-indol-4-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
 (1*H*-indol-4-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
 (1*H*-indol-4-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
 (1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
 (1*H*-indol-5-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
 (1*H*-indol-5-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
 (1*H*-indol-5-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
 (1*H*-indol-5-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
 (3-formyl-1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
 (1*H*-indol-6-yl)-(4-phenethylpiperazin-1-yl)methanone;
 (1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
 (1*H*-indol-6-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
 (1*H*-indol-6-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
 (1*H*-indol-6-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone,
 (1*H*-indol-6-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
 (3-formyl-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
 (3-cyano-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
 (1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone;
 (1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
 (1*H*-indol-7-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
 (1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
 (1*H*-indol-7-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
 (1*H*-indol-7-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
 (3-formyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
 (3-cyano-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone; and
 physiologically acceptable salts and solvates thereof.

50. (Previously Presented): A compound selected from:

(3-formyl-(1H-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(1H-indol-6-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(1H-indol-4-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-7-yl)-[4-(naphtha-2-ylethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-4-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-7-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone;
(3-aminocarbonyl-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone; (3-cyano-1H-indol-7-yl)-(4-phenethyl-piperazin-1-yl)methanone;
(3-cyano-1H-indol-7-yl)-[4-(2,4-difluorophenethyl)piperazin-1-yl]methanone;
7-{4-[2-(4-fluorophenyl)ethyl]piperazin-1-carbonyl}-1H-indole-2,3-dione; and
physiologically acceptable salts and solvates thereof.

51. (Previously Presented): A compound according to claim 50, wherein said compound is selected from:

(3-formyl-(1H-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(1H-indol-6-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;
(1H-indol-4-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-7-yl)-[4-(naphtha-2-ylethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-4-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-7-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-aminocarbonyl-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone,

hydrochloride;

(3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, methanesulfonate;

(3-cyano-1H-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;

(3-cyano-1H-indol-7-yl)-(4-phenethyl-piperazin-1-yl)methanone, hydrochloride; and

(3-cyano-1H-indol-7-yl)-[4-(2,4-difluorophenethyl)piperazin-1-yl]methanone, hydrochloride.

52. (Previously Presented): A compound according to claim 27, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.

53. (Previously Presented): A compound according to claim 52, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.

54. (Previously Presented): A compound according to claim 52, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.


55. (Previously Presented): A method according to claim 29, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.

56. (Previously Presented): A method according to claim 55, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.

57. (Previously Presented): A method according to claim 55, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.

58. (Previously Presented): A composition according to claim 30, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.
59. (Previously Presented): A composition according to claim 58, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.
60. (Previously Presented): A composition according to claim 58, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.
61. (Previously Presented): A method according to claim 34, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.
62. (Previously Presented): A method according to claim 61, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.
63. (Previously Presented): A method according to claim 61, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.
64. (Previously Presented): A method for treating scizophrenia comprising administering to a patient in need thereof an effective amount of a compound according to claim 27.

65. (Previously Presented): A method according to claim 64, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.
66. (Previously Presented): A method according to claim 65, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.
67. (Previously Presented): A method according to claim 65, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.
68. (Previously Presented): A method according to claim 27, wherein said compound is administered to said patient at a daily dose of between 0.02 and 100 mg/kg of body weight.
69. (Previously Presented): A method according to claim 29, wherein said compound is administered to said patient at a daily dose of between 0.02 and 100 mg/kg of body weight.
70. (Previously Presented): A method according to claim 34, wherein said compound is administered to said patient at a daily dose of between 0.02 and 100 mg/kg of body weight.
71. (Previously Presented): A method according to claim 64, wherein said compound is administered to said patient at a daily dose of between 0.02 and 100 mg/kg of body weight.
72. (New): A compound of the formula I



in which

R^1 is Het¹, or is a phenyl or naphthyl radical, each of which is unsubstituted or substituted by R^2 and/or R^3 ,

R^2 and R^3 are each, independently of one another, Hal, A, OA, OH or CN,

R^4 is H, CN, acyl having 1-6 C atoms, Hal, A, OH, CONH₂, CONHA or CONA₂,

R^5 is H, CN, acyl having 1-6 C atoms, Hal, A, OA, OH, CONH₂, CONHA or CONA₂,

R^4 and R^5 together are alternatively alkylene having 3-5 carbon atoms,


Het¹ is 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothieryl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzthiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolyl, 2-, 4-, 5-, 6-, 7- or

8-quinazolinyl,
 A is alkyl having 1-6 carbon atoms,
 Hal is F, Cl, Br or I,

wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and

where the indole ring may be replaced by an isatin unit ; [[,]] or a physiologically acceptable salt or solvate thereof;
 with the proviso that said compound is not (1*H*-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone.

73. (New): A compound of the formula I



in which

R¹ is Het¹, or is a phenyl or naphthyl radical, each of which is unsubstituted or substituted by R² and/or R³,
 R² and R³ are each, independently of one another, Hal, A, OA, OH or CN,
 R⁴ is H, CN, acyl having 1-6 C atoms, Hal, A, OH, CONH₂, CONHA or CONA₂,
 R⁵ is H,
 R⁴ and R⁵ together are alternatively alkylene having 3-5 carbon atoms,
 Het¹ is a monocyclic unsaturated heterocyclic ring system which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA or OH

and which contains one, two or three identical or different heteroatoms selected from nitrogen, oxygen or sulfur,

A is alkyl having 1-6 carbon atoms,

Hal is F, Cl, Br or I,

wherein the R¹-CH₂-CH₂-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and

where the indole ring may be replaced by an isatin unit; or
a physiologically acceptable salt or solvate thereof;

with the proviso that said compound is not (1*H*-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone.

74. (New): A compound according to claim 1, wherein R⁴ is attached to the 3-position of the indole structure.